Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507667-19-00

Acronym

CAIN457E22101

Enrollment

Registered

2024-05-03

Start date

2024-06-06

Completion date

2025-04-02

Last updated

2025-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Giant cell arteritis (GCA), Polymyalgia rheumatica (PMR)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Czechia, Italy, Portugal, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026